Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Labinaz M, Kilaru R, Pieper K, Marso SP, Kitt MM, Simoons ML, Califf RM, Topol EJ, Armstrong PW, Harrington RA. Labinaz M, et al. Among authors: califf rm. Circulation. 2002 Jan 22;105(3):322-7. doi: 10.1161/hc0302.102578. Circulation. 2002. PMID: 11804987 Clinical Trial.
Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.
Al-Khatib SM, Granger CB, Huang Y, Lee KL, Califf RM, Simoons ML, Armstrong PW, Van de Werf F, White HD, Simes RJ, Moliterno DJ, Topol EJ, Harrington RA. Al-Khatib SM, et al. Among authors: califf rm. Circulation. 2002 Jul 16;106(3):309-12. doi: 10.1161/01.cir.0000022692.49934.e3. Circulation. 2002. PMID: 12119245
Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes.
Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR Jr; GUSTO-IIb, GUSTO-III, PURSUIT. Global Use of Strategies to Open Occluded Coronary Arteries. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy; PARAGON-A Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Al Suwaidi J, et al. Among authors: califf rm. Circulation. 2002 Aug 20;106(8):974-80. doi: 10.1161/01.cir.0000027560.41358.b3. Circulation. 2002. PMID: 12186803
Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).
Labinaz M, Madan M, O'Shea JO, Kilaru R, Chin W, Pieper K, McGuire DK, Saucedo JF, Talley JD, Lui H, Kitt MM, Califf RM, Tcheng JT; ESPRIT Investigators. Labinaz M, et al. Among authors: califf rm. Am J Cardiol. 2002 Sep 15;90(6):585-90. doi: 10.1016/s0002-9149(02)02560-2. Am J Cardiol. 2002. PMID: 12231081 Clinical Trial.
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA. Batchelor WB, et al. Among authors: califf rm. Circulation. 2002 Sep 17;106(12):1470-6. doi: 10.1161/01.cir.0000029744.01096.1f. Circulation. 2002. PMID: 12234950 Clinical Trial.
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
Breeman A, Mercado N, Lenzen M, van den Brand MM, Harrington RA, Califf RM, Topol EJ, Simoons ML, Boersma E; PURSUIT Investigators. Breeman A, et al. Among authors: califf rm. Cardiology. 2002;98(4):195-201. doi: 10.1159/000067321. Cardiology. 2002. PMID: 12566649 Clinical Trial.
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT; Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Topol EJ, et al. Among authors: califf rm. Circulation. 2003 Jul 29;108(4):399-406. doi: 10.1161/01.CIR.0000084501.48570.F6. Epub 2003 Jul 21. Circulation. 2003. PMID: 12874182 Clinical Trial.
Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.
Pieper KS, Tsiatis AA, Davidian M, Hasselblad V, Kleiman NS, Boersma E, Chang WC, Griffin J, Armstrong PW, Califf RM, Harrington RA. Pieper KS, et al. Among authors: califf rm. Circulation. 2004 Feb 10;109(5):641-6. doi: 10.1161/01.CIR.0000112570.97220.89. Circulation. 2004. PMID: 14769687
1,332 results